. Author manuscript; available in PMC: 2019 Nov 21.

Published in final edited form as: Lancet Haematol. 2015 Nov 16;2(12):e516–e527. doi: 10.1016/S2352-3026(15)00197-0

Table 2:

Elotuzumab treatment and exposure in the intention-to-treat population

	Elotuzumab 10 mg/kg (n=36)	Elotuzumab 20 mg/kg (n=37)	Total (N=73)
Number of treatment cycles	21·5, 3–49	16·0, 1–51	17·0, 1–51
Total duration of study drug (months)	19·1, 1·9–45·8	14·5, <0·1–47·2	14·8, <0·1–47·2
Cumulative dose (mg/kg)	430·4, 86·3–1009·9	711·8, 19·9–2217·8	556·7, 19·9–2217·8
Dose intensity overall (mg/kg per week)	5·3, 3·9–8·2	10·6, 5·0–20·0	8·2, 3·9–20·0
Infusion duration (h)	1·7, 1·2–3·0	3·1, 1·8–4·1	2·3, 1·2–4·1

Data are median, range.